

USSN: 09/673,411


Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:**CLAIMS**

1. (Previously presented) A pharmaceutical composition comprising, apart from one or more pharmacologically active ingredients,
 - between 0.01 per cent and 60 per cent by weight of a compound of formula I



with n and m > 18 and < 46 and with a molecular weight between about 600 and about 8,000 in combination with 0.01% to 20% by weight of phosphatidylcholine for enhancement of active-ingredient absorption.

2. (Canceled)
3. (Previously presented) A pharmaceutical composition according to claim 1 with 0.1 per cent to 30 per cent by weight of the compound of formula I with n and m > 24 and < 36 and with the molecular weight between 1,000 and 4,000.
4. (Previously presented) A pharmaceutical composition according to claim 1,

USSN: 09/673,411

Page 3

wherein the composition is in a form selected from the group consisting of creams, emulsions, ointments, lotions, foams, gels, aspersion powders, and transdermal formulations.

5-8. (Canceled)

9. (Previously presented) A method according to Claim 13, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.

10-12. (Canceled)

13. (Previously presented) A method for enhancing absorption of a pharmacologically active ingredient, wherein the method comprises topically applying the pharmaceutical composition claimed in Claim 1 to a patient in need thereof, wherein the active ingredient is absorbed through derma, cutis, mucosa, rectum, vagina, or urethra.

14. (Currently amended) The method according to Claim 13, wherein the active ingredient ~~comprises~~ Troxerutine, Nimesulide or a non-steroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug ~~comprises~~ Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolac Acid, or Piroxicam[[.]], or a combination thereof.

15. (Previously presented) A pharmaceutical composition according to Claim 3, wherein the composition is in a form selected from the group consisting of creams, emulsions, ointments, lotions, foams, gels, aspersion powders, and transdermal formulations.

16-17. (Canceled)

18. (Previously presented) The composition according to Claim 1, wherein trans-

USSN: 09/673,411

Page 4

absorption of the active ingredient is increased by up to more than five times its normal value.

19. (Previously presented) The composition according to Claim 3, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.
20. (Previously presented) The method according to claim 13, wherein the active ingredient has an anabolic, an androgenic, an anesthetic, an anorectic, an anthelmintic, an antiallergic, an antiamebic, an antiandrogenic, an antianginal, an antiarrhythmic, an antiarteriosclerotic, an antiarthritic and an antirheumatic, an antibacterial, an anticholigenic, an anticonvulsant, an antidepressant, an antidiabetic, an antidiarrheal, an antidiuretic, an antiestrogenic, an antibiotic, an antiglaucoma, an antigonatropic, an antihistaminic, an antihyperlipoproteinemic, an antihyperthyroid, an antihypertensive, an antiinflammatory, an antimalarial, an antimigraine, an antinauseant, an antineoplastic, an antiparkinsonian, an antiprotozoal, an antipruritic, an antopsoriatic, an antipsychotic, an antipyretic, an antiseptic, an antispasmodic, an antithrombotic, an antitussive, an antiulcer, an antiviral, an anxiolytic, a bronchodilator, a Ca-blocking or regulating, an cardiotonic, a stimulating, a decongestant, a diuretic, or an enzymatic effect.
21. (Previously presented) The method according to Claim 13, wherein the active ingredient has an anabolic, an analgesic, an androgenic, an anesthetic, an anorectic, an anthelmintic, an antiallergic, an antiamebic, an antiandrogenic, an antianginal, an antiarrhythmic, an antiarteriosclerotic, an antiarthritic and an antirheumatic, an antibacterial, an anticholinergic, an anticonvulsant, an antidepressant, an antidiabetic, an antidiarrheal, an antidiuretic, an antiestrogenic, an antibiotic, an antiglaucoma, an antigonatropic, an antihistaminic, an antihyperlipoproteinemic, an antihyperthyroid, an antihypertensive, or an anti-Pentifylline effect.

USSN: 09/673,411

Page 5

22. (Currently amended) The method according to claim 13, wherein the active ingredient ~~comprises~~ is an alpha-adrenergic agonist, a beta-adrenergic blocker, an alcohol deterrent, an aldose reductase inhibitor, an anabolic drug, an dental analgesic, a narcotic analgesic, a non-narcotic analgesic, an androgen, an intravenous anesthetic, an anorectic, an anthelmintic, an antiacne drug, an antiallergic drug, an antiamebic drug, an antiandrogen, an antianginal drug, an antiarrhythmic drug, an antiarteriosclerotic drug, an antiarthritic/antirheumatic drug, an antibacterial drug, a beta-lactam, a synthetic antibacterial drug, an anticholinergic drug, an anticonvulsant drug, an antidepressant drug, an antidiabetic drug, an antidiarrheal drug, an antidiuretic drug, an antiestrogen drug, an antifungal drug, a synthetic antifungal drug, an antiglaucoma drug, an antigenadotropin, an antigout drug, an antihistamine, an antihyperlipoproteinemic drug, an antihypertensive drug, an antihyperthyroid drug, an antihypotensive drug, an antihypothyroid drug, a non-steroidal anti-inflammatory drug, an antimalarial drug, an antimigraine drug, an antinauseant drug, an antineoplastic drug, a hormonal antineoplastic drug, an antineoplastic adjunct drug including folic acid replenishers, an antiparkinsonian drug, an antipheochromocytoma drug, an antipneumocystis drug, an antiprostatic hypertrophy drug, an antiprotozoal drug, an antipuritic drug, and antipsoriatic drug, and antipsychotic drug, an antipyretic, an antirickettsial drug, an antiseborrheic drug, an antiseptic, an antispasmodic drug, an antithrombotic drug, an antitussive drug, and antiulcerative drug, an antiulolithic drug, an antivenin drug, an antiviral drug, an anxiolytic drug, a benzodiazepine antagonist, a bronchodilator, a calcium channel blocker, a calcium regulator, a cardiotonic, a chelating agent, a cholecystokinin antagonist, a cholelitholytic agent, a choleric, a cholinergic agent, a cholinesterase inhibitor, a cholinesterase reactiver, a central nervous system stimulant, a central nervous system agent, a decongestant, a dental caries prophylaxis, a depigmentor, a diuretic, a dopamine receptor agonist, an ectoparasiticide, an enzyme, an hepatic enzyme inducer, an estrogen, a gastric secretion inhibitor, a glucocorticoid, a gonad stimulating principle, a gonadotropic hormone, a growth hormone inhibitor, a

USSN: 09/673,411

Page 6


growth hormone releasing factor, a growth stimulant, a hemolytic agent, a heparin antagonist, a hepatoprotectant, an immunomodulator, an immuno-suppressant, an ion exchange resin, a lactation stimulating hormone, an LH-RH agonist, a lipotropic agent, a lupus erythematosus suppressant, a mineralcorticoid, a miotic drug, a monoamine oxidase inhibitor, a mucolytic agent, a skeletal muscle relaxant, a narcotic antagonist, a neuroprotective agent, a nootropic agent, an ophthalmic agent, an ovarian hormone, an oxytocic drug, a pepsin inhibitor, a peristaltic stimulant, a progestogen, a prolactin inhibitor, a prostaglandin and prostaglandin analog, a protease inhibitor, a respiratory stimulant, a sclerosing agent, a sedative and hypnotic drug, a thrombolytic agent, a thyrotropic hormone, a uricosuric drug, a cerebral vasodilator, a coronary vasodilator, a peripheral vasodilator, a vasoprotectant, a vitamin, a vitamin source, a vitamin extract, or a vulnerary agent[.], or a combination thereof.

23. (Previously presented) A method for enhancing absorption of a pharmacologically active ingredient, wherein the method comprises topically applying the pharmaceutical composition claimed in Claim 3 to a patient in need thereof, wherein the active ingredient is absorbed through derma, cutis, mucosa, rectum, vagina, or urethra.
24. (Currently amended) A method as claimed in Claim 13, wherein the active ingredient ~~comprises~~ is an anthelmintic that is effective against Cestodes, Nematodes, Onchocerca, Schistosoma, or Trematodes, or wherein the active ingredient comprises an antiprotozoal drug that is effective against Leishmania, Trichomonas, or Trypanosoma[.], or a combination thereof.
25. (Currently amended) A pharmaceutical composition as claimed in Claim 1, wherein ~~wherein~~ trans-absorption of the active ingredient is increased by up to more than ten times its normal value.

USSN: 09/673,411

Page 7

26. (Currently amended) A pharmaceutical composition as claimed in Claim 1, wherein ~~wherein~~ trans-absorption of the active ingredient is increased by up to more than 20 times its normal value.
27. (Previously presented) A method as claimed in Claim 13, wherein trans-absorption of the active ingredient is increased by up to more than ten times its normal value.
28. (Previously presented) A method as claimed in Claim 13, wherein trans-absorption of the active ingredient is increased by up to more than 20 times its normal value.
29. (Currently amended) A pharmaceutical composition as claimed in Claim 1, wherein the active ingredient comprises troxerutine.
30. (Currently amended) A method as claimed in Claim 13, wherein the active ingredient comprises troxerutine.
31. (Previously presented) A pharmaceutical composition consisting essentially of:
 - (1) one or more pharmacologically active ingredients;
 - (2) between about 0.01 per cent and about 60 per cent by weight of a compound of formula I



(1)

wherein n and m are each greater than 18 and are each less than 46 and wherein the compound of the formula I has a molecular weight between about 600 and about 8,000;

- (3) phosphatidylcholine;
- (4) optionally tocopherol acetate;


USSN: 09/673,411

Page 8

- (5) optionally polyacrylamide, C₁₃-C₁₄ isoparaffin, and laureth-7;
- (6) optionally methyl-p-hydroxybenzoate;
- (7) optionally propyl-p-hydroxybenzoate;
- (8) optionally phenoxyethanol;
- (9) optionally nor-chenodeoxycolic acid;
- (10) optionally transcutol; and
- (11) optionally water.

32. (Previously presented) A pharmaceutical composition consisting essentially of:

- (1) one or more pharmacologically active ingredients;
- (2) between about 0.01 per cent and about 60 per cent by weight of a compound of formula I



wherein n and m are each greater than 18 and are each less than 46 and wherein the compound of the formula I has a molecular weight between about 600 and about 8,000;

- (3) phosphatidylcholine;
- (4) optionally tocopherol acetate;
- (5) optionally polyacrylamide, C₁₃-C₁₄ isoparaffin, and laureth-7;
- (6) optionally methyl-p-hydroxybenzoate;
- (7) optionally propyl-p-hydroxybenzoate;
- (8) optionally phenoxyethanol;
- (9) optionally nor-chenodeoxycolic acid;
- (10) optionally transcutol;
- (11) optionally lactic acid;
- (12) optionally ethyl alcohol; and
- (13) optionally water.

USSN: 09/673,411

Page 9

33. (Currently amended) A pharmaceutical composition as claimed in Claim 31, wherein the active ingredient comprisesis troxerutine.
34. (Previously presented) A pharmaceutical composition according to claim 31, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
35. (Previously presented) A pharmaceutical composition according to claim 33, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
36. (Currently amended) A pharmaceutical composition as claimed in Claim 32, wherein the active ingredient comprisesis troxerutine.
37. (Previously presented) A pharmaceutical composition according to claim 32, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
38. (Previously presented) A pharmaceutical composition according to claim 36, wherein the phosphatidylcholine constitutes 0.01 per cent to 10 per cent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
39. (Currently amended) The method according to Claim 13, wherein the active ingredient comprisesis Troxerutine, Nimesulide, Ketoprofen, or Etodolac Acid[[.]], or a

USSN: 09/673,411

Page 10

combination thereof.

40. (Currently amended) The pharmaceutical composition as claimed in Claim 1, wherein the active ingredient ~~comprises~~ Troxerutine, Nimesulide, Ketoprofen, or Etodolic Acid[.], or a combination thereof.

41. (Currently amended) The pharmaceutical composition as claimed in Claim 31, wherein the active ingredient ~~comprises~~ Troxerutine, Nimesulide, Ketoprofen, or Etodolic Acid[.], or a combination thereof.

42. (Currently amended) The pharmaceutical composition as claimed in Claim 32, wherein the active ingredient ~~comprises~~ Troxerutine, Nimesulide, Ketoprofen, or Etodolic Acid[.], or a combination thereof.

43. (Currently amended) The pharmaceutical composition as claimed in Claim 1, wherein ~~the phosphatidylcholine comprises~~ is 0.01% to 10% by weight of the pharmaceutical composition.

44 - 57 (Canceled)

58. (Currently amended) The pharmaceutical composition as claimed in claim 31, wherein the composition consists essentially of the one or more active ingredients, the compound formula I, the [[the]]phosphatidylcholine, and optionally the water.